HealthLawProf Blog

Editor: Katharine Van Tassel
Akron Univ. School of Law

A Member of the Law Professor Blogs Network

Monday, August 4, 2008

House Panel Seeks Vytorin Study Data

The Wall Street Journal reports that the House Energy and Commerce Committee wants the FDA to turn over the results of an analysis that possibly links the cholesterol drug Vytorin to incidents of cancer.  Alicia Mundy writes,

VytorinThe House Energy and Commerce Committee wants the Food and Drug Administration to turn over the results of an analysis looking into the potential links between cancer and the cholesterol drug Vytorin.

A report called the Seas study stunned investors and the medical community in late July, because researchers looking at Vytorin's efficacy in reducing cholesterol had unexpectedly found an increased risk of cancer and deaths from cancer in patients taking Vytorin, compared with those given a placebo.

Vytorin is made by a joint venture of Merck & Co. and Schering-Plough Corp. The companies delayed their earnings announcement on July 22 to inform investors about the Seas study's findings.

At the time, the companies said they had funded an analysis of the Seas study by Richard Peto, an epidemiologist at Oxford University. The Oxford researchers, using data on 20,000 patients from two other continuing Vytorin studies, said the study's suggestions of a link to cancer is largely due to chance and "implausible."

The House Energy and Commerce Committee wants the Food and Drug Administration to turn over the results of an analysis looking into the potential links between cancer and the cholesterol drug Vytorin.

A report called the Seas study stunned investors and the medical community in late July, because researchers looking at Vytorin's efficacy in reducing cholesterol had unexpectedly found an increased risk of cancer and deaths from cancer in patients taking Vytorin, compared with those given a placebo.

Vytorin is made by a joint venture of Merck & Co. and Schering-Plough Corp. The companies delayed their earnings announcement on July 22 to inform investors about the Seas study's findings.

At the time, the companies said they had funded an analysis of the Seas study by Richard Peto, an epidemiologist at Oxford University. The Oxford researchers, using data on 20,000 patients from two other continuing Vytorin studies, said the study's suggestions of a link to cancer is largely due to chance and "implausible."

http://lawprofessors.typepad.com/healthlawprof_blog/2008/08/house-panel-see.html

| Permalink

TrackBack URL for this entry:

http://www.typepad.com/services/trackback/6a00d8341bfae553ef00e553cd8b9c8833

Listed below are links to weblogs that reference House Panel Seeks Vytorin Study Data:

Comments

Post a comment